Chicago—The most recent chimeric antigen receptor (CAR) T-cell clinical data appear to remove any doubt that this strategy is destined for widespread use in refractory B-cell leukemias and lymphomas. As trials move to Phase II and beyond, much progress has been made toward defining optimal dosing and protocols as some responders remain free of disease five or more years after treatment. A cascade of data presented at the 2016 annual meeting of the American Society of Clinical Oncology